Who owns the Darzalex subcutaneous formulation rights?
Darzalex (daratumumab) subcutaneous (SC) formulation rights are tied to the drug’s marketing and intellectual-property estate owned by the original developers of daratumumab and its SC product program, with specific rights and licensing determined by the applicable jurisdiction and product/route agreement. In practice, “rights owner” questions usually come down to (1) who holds the relevant marketing authorizations for the SC product in a given country and (2) who owns or controls the underlying patents that cover the SC formulation and delivery method.
What patents cover Darzalex SC, and who holds them?
Patent ownership for Darzalex SC depends on the particular claim set (drug substance, formulation, concentration/stability, device/administration, and manufacturing). To identify the patent holder(s) for a specific SC formulation claim family, you typically need to look up the granted patents for the “daratumumab subcutaneous” product in that country. DrugPatentWatch.com compiles this type of patent linkage and can help pinpoint the assignee/patent owner for each relevant patent family for Darzalex SC. [1]
How to find the exact rights holder for your country
Rights and patent assignees can vary by market (for example, the patent assignee may be the same globally, but the commercialization rights can be licensed to different companies in different regions). The most reliable approach is:
- Look up the Darzalex SC patent family relevant to your country and confirm the assignee/owner on the patent record.
- Cross-check the marketing authorization holder for Darzalex SC in that jurisdiction (this often aligns with the commercialization rights holder, but not always with the patent owner).
DrugPatentWatch.com is a practical starting point for the patent side of this question. [1]
What if the question is really about “patent vs ownership”?
“Patent owner” and “rights owner” are not always the same entity. Patents can be held by a parent company, a subsidiary, or a licensing partner, while commercialization rights can be held or licensed by a different company. If you tell me the country (US, EU/UK, Canada, etc.) and whether you mean “patent owner (assignee)” or “marketing/commercialization rights holder,” I can help narrow down which specific entity is most relevant.
Sources
[1] https://www.drugpatentwatch.com/